June 1, 2016
San Diego, Calif., June 1, 2016 – Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, announced today that its President & CEO, Joseph E. Payne, has been invited to present during the “Delivery: The Next Frontier of Biotherapeutics” session at the 2016 BIO International Convention in San Francisco on Tuesday, June 7, at 1:30 pm PST, at Moscone Center, West Building Room 3002, organized by Janssen Biotherapeutics.
In addition, Joseph E. Payne has agreed to participate in a panel discussion titled “Nailed it! Rock Star Panel” to be held on Wednesday, June 8, at 2:30 pm PST, West Building Room 3002, organized by Johnson & Johnson Innovation | JLABS.
The company presentation and panel discussion will highlight the latest developments regarding Arcturus’ UNA chemistry and LUNAR™ nanoparticle delivery technologies — and their application toward the development of novel RNA therapeutics and vaccines.
About BIO International Convention
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities. Past speakers include President George W. Bush, President Bill Clinton, Former Prime Minister of Great Britain and Northern Ireland Tony Blair, Michael J. Fox, Sir Elton John, Her Majesty Queen Noor of Jordan, and General Colin Powell, among many others. The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world’s largest biotechnology exhibition – the BIO Exhibition.
About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery. Arcturus’ versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (77 patents and patent applications, issued in the U.S., Europe, Japan and other countries). Arcturus’ proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company’s commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc. (A Johnson and Johnson Company) and Ultragenyx Pharmaceutical, Inc. For more information, visit www.ArcturusRx.com.